Published in Neurology on July 18, 2012
Re-evaluating the treatment of acute optic neuritis. J Neurol Neurosurg Psychiatry (2014) 0.86
Retinal architecture and mfERG: Optic nerve head component response characteristics in MS. Neurology (2014) 0.78
Improved characterization of visual evoked potentials in multiple sclerosis by topographic analysis. Brain Topogr (2013) 0.76
Acute optic neuritis: a clinical paradigm for evaluation of neuroprotective and restorative strategies? Neural Regen Res (2015) 0.75
Low-contrast multifocal visual evoked potentials: identifying more shades of gray in MS. Neurology (2012) 0.75
Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis. Mult Scler (2017) 0.75
Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology (2006) 4.72
Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol (2006) 3.73
Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol (2008) 2.20
Tracking retinal nerve fiber layer loss after optic neuritis: a prospective study using optical coherence tomography. Mult Scler (2008) 2.03
Multifocal VEP and OCT in optic neuritis: a topographical study of the structure-function relationship. Doc Ophthalmol (2008) 1.12
Electrophysiological evidence for heterogeneity of lesions in optic neuritis. Invest Ophthalmol Vis Sci (2007) 1.10
Interrelationship of optical coherence tomography and multifocal visual-evoked potentials after optic neuritis. Invest Ophthalmol Vis Sci (2009) 0.96
Multifocal visual evoked potential latency analysis: predicting progression to multiple sclerosis. Arch Neurol (2006) 0.95
Evaluation of optic neuropathy in multiple sclerosis using low-contrast visual evoked potentials. Neurology (2009) 0.94
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med (2006) 6.25
Tract probability maps in stereotaxic spaces: analyses of white matter anatomy and tract-specific quantification. Neuroimage (2007) 5.23
Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology (2006) 4.72
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet (2011) 3.76
Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain (2011) 3.48
Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol (2006) 3.38
Photoreceptor layer thinning in idiopathic Parkinson's disease. Mov Disord (2014) 3.36
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol (2009) 3.35
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A (2006) 3.13
A topology-preserving approach to the segmentation of brain images with multiple sclerosis lesions. Neuroimage (2009) 3.07
The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest (2003) 3.02
Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol (2010) 2.99
Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol (2010) 2.96
Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol (2012) 2.79
Factors that influence adherence with disease-modifying therapy in MS. J Neurol (2009) 2.67
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol (2006) 2.62
Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod. Neurology (2012) 2.54
Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology (2012) 2.48
Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol (2007) 2.44
Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol (2009) 2.43
The King-Devick test and sports-related concussion: study of a rapid visual screening tool in a collegiate cohort. J Neurol Sci (2011) 2.43
In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology (2013) 2.43
The neuro-ophthalmology of multiple sclerosis. Lancet Neurol (2005) 2.39
Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis. JAMA Neurol (2013) 2.22
Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain (2011) 2.21
Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol (2008) 2.20
Corneal intrastromal gatifloxacin crystal deposits after penetrating keratoplasty. Eye Contact Lens (2004) 2.10
Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol (2005) 2.08
Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. Neurology (2013) 2.06
Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology (2005) 2.06
Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy. Arch Neurol (2002) 2.05
Laser pointer visual field screening. J Neuroophthalmol (2003) 2.03
High resolution diffusion tensor imaging of axonal damage in focal inflammatory and demyelinating lesions in rat spinal cord. Brain (2007) 2.03
Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness. Mult Scler (2011) 2.02
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol (2005) 2.02
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol (2013) 2.00
Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol (2010) 1.97
Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol (2008) 1.88
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis. Arch Neurol (2009) 1.85
Retinal nerve fiber layer thickness in children with optic pathway gliomas. Am J Ophthalmol (2011) 1.80
Diffusion tensor magnetic resonance imaging of Wallerian degeneration in rat spinal cord after dorsal root axotomy. J Neurosci (2009) 1.79
Activated T-cells inhibit neurogenesis by releasing granzyme B: rescue by Kv1.3 blockers. J Neurosci (2010) 1.69
The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A (2005) 1.69
Retinal layer segmentation of macular OCT images using boundary classification. Biomed Opt Express (2013) 1.67
Validation and test characteristics of a 10-item neuro-ophthalmic supplement to the NEI-VFQ-25. Am J Ophthalmol (2006) 1.66
Optical coherence tomography in multiple sclerosis. Lancet Neurol (2006) 1.65
Multiparametric magnetic resonance imaging analysis of the corticospinal tract in multiple sclerosis. Neuroimage (2007) 1.62
Optical coherence tomography (OCT): imaging the visual pathway as a model for neurodegeneration. Neurotherapeutics (2011) 1.57
Near infrared muscle spectroscopy in patients with Friedreich's ataxia. Muscle Nerve (2002) 1.53
Functional topography of the ventral striatum and anterior limb of the internal capsule determined by electrical stimulation of awake patients. Clin Neurophysiol (2009) 1.52
Functional visual loss in idiopathic intracranial hypertension. Ophthalmology (2009) 1.51
Renal deterioration in multiple sclerosis patients with neurovesical dysfunction. Mult Scler (2013) 1.47
Optic nerve head component responses of the multifocal electroretinogram in MS. Neurology (2013) 1.46
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 1.46
Retinal pathology in multiple sclerosis: insight into the mechanisms of neuronal pathology. Brain (2010) 1.45
Pediatric optic neuritis and risk of multiple sclerosis: meta-analysis of observational studies. J AAPOS (2011) 1.45
The role of unilateral temporal artery biopsy. Ophthalmology (2003) 1.44
Damage to the optic radiation in multiple sclerosis is associated with retinal injury and visual disability. Arch Neurol (2009) 1.43
Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy. PLoS Pathog (2012) 1.42